Control
Jun 9 2021 |
et al., Frontiers in Medicine, doi:10.3389/fmed.2021.639970 | Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study |
| 89% higher mortality (p<0.0001). Retrospective 3,451 hospitalized COVID-19 patients in Italy showing higher mortality with darunavir/cobicistat. | ||
Apr 1 2021 |
et al., AIDS Research and Human Retroviruses, doi:10.1089/AID.2020.0305 | Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia |
| 150% higher mortality (p=0.0001) and 48% higher combined mortality/intubation (p=0.03). Retrospective 273 hospitalized COVID-19 patients showing higher mortality with darunavir/cobicistat treatment. | ||
Dec 31 2020 |
et al., Yonsei Medical Journal, doi:10.3349/ymj.2020.61.9.826 | Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection |
| 87% lower mortality (p=0.009). Retrospective 110 critically ill COVID-19 patients in South Korea showing lower mortality with darunavir/cobicistat treatment. | ||
Jul 29 2020 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa321 | Reply to: “Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19” |
| 32% higher mortality (p=0.21). Retrospective 328 hospitalized COVID-19 patients in Italy showing no mortality benefit with darunavir/ritonavir treatment. | ||
Jun 21 2020 |
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa241 | Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-19 |
| 22% worse viral clearance (p=0.64). RCT 30 mild COVID-19 patients showing no benefit of darunavir/cobicistat compared to standard care for viral clearance. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.